Very valid point. You can imagine a situation where Austrianova, knowing of pending PMCB news, goes to shop CiaB to european big pharma and gets some nibbles, and then comes to PMCB to re-negotiate.
Austrianova wants top dollar for CiaB tech and PMCB has gotten us to the verge of a Phase 2b trial. Both have positions of strength and both want to maximize profits in the long run.
It's hard to say who got the better deal. To me the deal looks fair and it very much looks like the term sheet changes were made to facilitate future PMCB partnerships.
News 
Market Data 
Discover 
